Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Benchmark Statement Prosthetics and Orthotics Services in Lebanon



Lebanese, Syrian and Palestinian people with physical disabilities living in Lebanon are confronted with a variety of barriers that hinder their access to healthcare services especially, rehabilitation services, which include prosthetic and orthotic devices. Furthermore, the absence of a unified and standardized prosthetic and orthotic coverage procedure makes access even more difficult for those individuals.
 
Therefore, the International Committee of Red Cross (ICRC) in Lebanon has worked in close partnership with the Lebanese Ministry of Public Health (MoPH), Lebanese Syndicate of Prosthetics and Orthotics and University of Balamand, with the support of the Rehabskills Limited team, to complete a Benchmark Statement on the Prosthetics and Orthotics Sector in Lebanon (English version).
 
The Benchmark Statement aims at comparing the situation in Lebanon with the World Health Organization (WHO) Standards for Prosthetics and Orthotics as well as making recommendations for its improvement. Consequently, the Benchmark Statement provides a strong foundation that will enable the upgrade of this sector therefore, leading to the establishment of a national strategy for 2030 and regulation of the profession. The Statement covers four main areas of the health system (also known as the four “Ps”): Policy; Products; Personnel and Provision of services. The vision, mission and aims of each ‘P’ will be incorporated into training and mentoring packages that will enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
In April 2021, the ICRC and project partners organized, in collaboration with the Disability Hub, the first online webinar focusing on the Policy area in order to reinforce the visibility and promote the dissemination of the project. The webinar successfully attracted a big number of participants, at a time when health services and systems were and still are severely disrupted in the country due to the Beirut blast, the Covid pandemic, and of course the deteriorating economic situation and political deadlock.



Throughout this year and in 2022, other related online webinars will be organized by the ICRC and project partners to enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
Despite all the difficulties and challenges, Lebanon has taken the first steps on the path of aligning itself with the relevant WHO standards by undertaking this benchmarking process thus, highlighting  its commitment to working towards transforming and improving the provision of prosthetic and orthotic services in the country.
    ...
    37
    ...
ATC Name B/G Ingredients Dosage Form Price
B01AC27 UPTRAVI B Selexipag - 800mcg 800mcg Tablet, film coated 275,097,581 L.L
C09BB02 ZANIPRESS B Lercanidipine HCl - 10mg, Enalapril maleate - 10mg Tablet, film coated 2,280,949 L.L
C10AA05 TORVALIP 10 G Atorvastatin (calcium) - 10mg 10mg Tablet, film coated 767,910 L.L
G04BE03 SILDENAFIL ARROW LAB G Sildenafil - 100mg 100mg Tablet, film coated 3,192,970 L.L
J01CR02 KLAVOX G Amoxicillin (trihydrate) - 875mg, Clavulanic Acid (potassium) - 125mg 1g Tablet, film coated 338,648 L.L
J01MA02 CIPROMID G Ciprofloxacine (HCl) - 500mg 500mg Tablet, film coated 331,929 L.L
N02BE01 PANADOL ADVANCE B Paracetamol - 500mg 500mg Tablet, film coated 438,093 L.L
A10BD11 JENTADUETO B Metformin - 850mg, Linagliptin - 2.5mg Tablet, film coated 3,542,369 L.L
B01AC27 UPTRAVI B Selexipag - 1000mcg 1000mcg Tablet, film coated 275,097,581 L.L
C10AA05 TOVAST G Atorvastatin (calcium) - 10mg 10mg Tablet, film coated 1,127,484 L.L
L04AA06 IMUNOCELL G Mycophenolate mofetil - 500mg 500mg Tablet, film coated 3,791,428 L.L
N02BE01 PANADOL ADVANCE B Paracetamol - 500mg 500mg Tablet, film coated 137,072 L.L
N06AB10 CITOXAL G Escitalopram (oxalate) - 5mg 5mg Tablet, film coated 895,895 L.L
A10BD11 INAGLIMET G Metformin - 850mg, Linagliptin - 2.5mg Tablet, film coated 1,670,844 L.L
B01AC27 UPTRAVI B Selexipag - 1200mcg 1200mcg Tablet, film coated 275,097,581 L.L
C10AA05 TULIP G Atorvastatin (calcium) - 10mg 10mg Tablet, film coated 899,031 L.L
G04BE03 VIRECTA G Sildenafil - 100mg 100mg Tablet, film coated 584,571 L.L
J01MA02 ESTECINA 500MG G Ciprofloxacine (HCl) - 500mg 500mg Tablet, film coated 618,168 L.L
N02BE01 PANADOL ADVANCE B Paracetamol - 500mg 500mg Tablet, film coated 389,714 L.L
N06AB10 PRAMACYT 5 G Escitalopram (oxalate) - 5mg 5mg Tablet, film coated 895,895 L.L
A10BD13 VIPDOMET B Metformin HCl - 500mg, Alogliptin benzoate - 12.5mg Tablet, film coated 3,112,339 L.L
B01AC27 UPTRAVI B Selexipag - 1400mcg 1400mcg Tablet, film coated 275,097,581 L.L
C02AC05 CYNT B Moxonidine - 0.2mg 0.2mg Tablet, film coated 901,735 L.L
J01MA02 LADININ G Ciprofloxacine (HCl) - 500mg 500mg Tablet, film coated 572,393 L.L
M01AE51 IBUGESIC COLD AND SINUS G Ibuprofen - 200mg, Pseudoephedrine HCl - 30mg Tablet, film coated 154,542 L.L
N06AB10 PRYLEX 5 G Escitalopram (oxalate) - 5mg 5mg Tablet, film coated 895,895 L.L
A04AA02 KYTRIL B Granisetron (HCl) - 1mg 1mg Tablet, film coated 2,765,628 L.L
A10BD13 VIPDOMET B Metformin HCl - 1,000mg, Alogliptin benzoate - 12.5mg Tablet, film coated 3,304,509 L.L
B01AC27 UPTRAVI B Selexipag - 1600mcg 1600mcg Tablet, film coated 275,097,581 L.L
C02AC05 CYNT B Moxonidine - 0.3mg 0.3mg Tablet, film coated 1,218,134 L.L
    ...
    37
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025